Stop the games. Make NC healthier by expanding weight-loss drug coverage | Opinion
Despite the benefits of such medicines, like Wegovy, Saxenda and Zepbound, many people who could most benefit from them can’t ...
GP busts six common myths about Ozempic, Mounjaro, Wegovy and weight loss jabs
A staggering 64% of adults in England are classed as either overweight or obese according to the most recent NHS figures. And ...
STAT3h
More state Medicaid programs consider covering GLP-1 drugs
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...
Weight-Loss Drugs May Help Alcohol and Opioid Addiction
Research hints that medications like Zepbound and Wegovy could provide new ways to treat opioid and alcohol abuse.
Seeking Alpha on MSN18h
Novo's Rybelsus results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Head-to-toe… all the little-known ways ‘Ozempic-style’ fat jabs can boost your health
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...
Inside story of how Ozempic decimated the diet industry: Women are bragging about how fantastic they feel, lying about weight to 'score' the jab... and say they'll NEVER …
Earlier this month, WeightWatchers made the extraordinary announcement that it would be offering its own version of the 'fat ...
Novo Nordisk CEO Lars Jorgensen blames ‘complex US healthcare system’ for steep Ozempic prices — which Senator Bernie Sanders says may lead to higher insurance …
Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...
The National Observer: Popular worker benefit too pricey for many employers
SURVEY SAYS: Just 18% of the health-care plans sponsored by employers with 200 workers or more cover such drugs, according to ...
Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Viatris Inc.'s volatile stock performance, CEO's strategic focus on growth, and promising pipeline highlight potential for ...